HCM
NTLA icon

Hitchwood Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Hitchwood Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$12M – 75
2021
Q1 		$12M Hold
150,000
– – 0.27% 54
2020
Q4 		$8.16M Buy
+150,000
New +$5.45M 0.14% 58

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Hitchwood Capital Management's NTLA Position: Q2 2021 in Review

Hitchwood Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2021, closing a stake of 150,000 shares — an estimated $12M sold.

Hitchwood Capital Management first reported a position in NTLA in Q4 2020 and held it in 2 quarters. The position peaked at $12M in Q1 2021. 335 funds tracked by Wall St. Rank hold NTLA as of Q2 2021.

  • Hitchwood Capital Management reported no remaining Intellia Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Hitchwood Capital Management sold 150,000 Intellia Therapeutics shares in Q2 2021, an estimated $12M.
  • Hitchwood Capital Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 2 quarters.
  • Hitchwood Capital Management's Intellia Therapeutics position peaked at $12M in Q1 2021.
  • 335 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2021.

Based on Hitchwood Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.